Navigation Links
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
Date:5/6/2009

Data from landmark trial provide important insight for physicians in treating heart attack patients

NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New England Journal of Medicine. The HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation with research grant support from Boston Scientific and The Medicines Company (Nasdaq: MDCO), is designed to evaluate the safety and efficacy of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients undergoing catheter treatment for an acute myocardial infarction (AMI), or heart attack.

With more than 3,000 patients enrolled worldwide, HORIZONS AMI is the largest randomized trial to compare the use of drug-eluting stents (DES) to bare-metal stents (BMS) for the treatment of heart attack patients, a complicated patient population with known increased risks of death and stent thrombosis. The one-year results demonstrated that the TAXUS Express Stent significantly reduced angiographic restenosis and the primary efficacy endpoint of ischemia-driven target lesion revascularization (TLR, or rate of re-intervention of the stented segment) compared to an otherwise identical bare-metal Express(R) Stent control. The primary safety measure showed no difference between the TAXUS Express Stent and the bare-metal Express Stent in overall major adverse cardiovascular events (MACE), or its components, including death, repeat heart attack, stroke or stent thrombosis at one year.

"The HORIZONS AMI trial provided outcomes data showing treatment with a TAXUS paclitaxel-eluting stent had superi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Chindex International, ... ) announced that, at a special meeting of stockholders ... merger agreement (the "Merger  Agreement") by and among the ... Acquisition, Inc. ("Merger Sub"). Parent is an affiliate of ... Ms. Roberta Lipson , the CEO of the ...
(Date:9/16/2014)... Research and Markets has announced the addition of the ... offering. Animal vaccines are biological preparations used ... prepared from weakened or dead microbes that can cause a ... animal vaccines are also formulated using a part of a ... These components act as stimulating agents that trigger ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
(Date:9/16/2014)... September 16, 2014 Cliff Lake Dental Care ... Kristaleen is the newest dental hygienist to join Dr. Rauchwarter's ... to working with her and knows she will bring many ... , Kristaleen grew up in River Falls, WI. She ... College in 2003 and practiced dental assisting in the Twin ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... September 14, 2014 A new study found ... (SB) stenting of true coronary bifurcation lesions yields ... The DKCRUSH-VI clinical trial is the first study ... Findings were reported today at the 26th annual ... the Cardiovascular Research Foundation (CRF), TCT is the ...
(Date:9/16/2014)... with endocrine therapy and radiation therapy as part ... care for women with hormone-receptor positive (HR+) invasive ... Fox Chase Cancer Center, however, shows that combination ... with the disease. , The results, which ... for Radiation Oncology,s 56th Annual Meeting on Sunday, ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3
... patients covered by compensation have worse physical and life-quality ... to new research. ,Orthopaedic injury, usually ... form of hospitalisation in Australia, according to the study ... ,,The authors Professor Peter Cameron, Head of ...
... health doctors argue for routine opt-out HIV testing in ... departments and hospital wards. ,In the first article, ... people in the UK with HIV do not know they ... for pregnant women and people attending genitourinary (GUM) clinics. ...
... taken before meals, can improve blood glucose control for people ... with short-acting injected insulin that is taken in addition ... according to a new review of the body of published ... 2 diabetes typically have to take extra insulin at mealtimes ...
... AVGO), a late stage biotechnology company that develops central ... selection of the optimal dose of HD-02, its ... ,This dose was determined in an open-label ... Dr. Diana Rosas of Massachusetts General Hospital (MGH), and ...
... mass displacement of people in sub-Saharan Africa do not necessarily ... refugee agency said on Friday. ,Contradicting a ... the UN High Commissioner for Refugees (UNHCR) said that out ... actually had a lower rate than surrounding host communities. ...
... who was detained for 30 years in his native Cuba, realized ... a ceremony in Miami. ,Now, he says, his ... the former fisherman is convinced he will outlive the ailing Cuban ... far less healthy than I am, he can hardly talk," Temprana ...
Cached Medicine News:Health News:Doctors Call for Opt-out Approach to HIV Testing 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 3Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Medicine Products: